Compare Enveric Biosciences Inc (ENVB) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Equinor ASA — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Equinor ASA trades at $42.85 (market cap $100.03B). The key difference: Equinor ASA is far larger — about 14952.2× Enveric Biosciences Inc's market cap, and Equinor ASA pays a 3.75% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Equinor ASA for 59 Days on average.
| ENVB | EQNR | |
|---|---|---|
Market Cap | $6.69M | $100.03B |
Volume | 41,141 | 4,457,638 |
Sector | Health | Energy |
52-Week High | $10.80 | $45.75 |
52-Week Low | $1.27 | $22.41 |
Typical Hold Time | 14 Days | 59 Days |
Enterprise Value | -$1.60M | $108.72B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Equinor (EQNR) trades at $42.93, down 0.19% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The stock presents compelling value with a P/E of 11.28 and EV/EBITDA of 2.35, well below industry averages. Recent developments include expansion in LNG operations and carbon capture projects, while maintaining strong operational cash flow of $20B. The company continues shareholder returns through dividends and buybacks.
EQNR offers significant upside potential with a consensus price target of $70.50 representing 64% upside, supported by improving earnings outlook and strategic LNG expansion. Key risks include volatile energy prices and execution challenges in new projects. Analyst sentiment is mixed with 30% buy ratings, but recent Zacks upgrades to Strong Buy highlight growing optimism about earnings recovery through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
